Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Zynerba receives FDA guidance on confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome

% of readers think this story is Fact. Add your two cents.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has received guidance from the US Food and Drug Administration (FDA) on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS). 

The trial, which will be called RECONNECT (A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents with Fragile X Syndrome), is designed to evaluate the efficacy and safety of Zygel in children and adolescents with FXS. 

Zynerba said the study is planned to confirm the positive results observed in a population of responders in its CONNECT-FX trial, a randomized, double-blind, placebo-controlled trial that assessed the efficacy and safety of Zygel as a treatment for the behavioral symptoms of FXS previously conducted by the company. 

READ: Zynerba Pharmaceuticals says it is fully funded into 2024; lays out plans to advance four Zygel indications in 4Q results

The company said it believes that the results, if positive, from RECONNECT will be sufficient to support the submission of a New Drug Application for Zygel in patients with FXS.

“Following productive discussions and alignment with the FDA, we believe we have a clear path forward for Zygel in Fragile X syndrome. We are excited to advance Zygel into the RECONNECT trial, a pivotal, multi-national, confirmatory Phase 3 trial in patients with FXS in the third quarter of 2021,” said CEO Armando Anido in a statement.  

“If the results are positive, Zygel could become the first FDA approved treatment option for the significant unmet medical need that affects patients with FXS and their families.”

The RECONNECT trial will be an 18-week trial that will enroll approximately 200 children and adolescents of which approximately 160 patients will have complete (100%) methylation of their FMR1 gene and approximately 40 patients will have partial methylation of their FMR1 gene. 

The primary endpoint for the trial will be the change in the Aberrant Behavior Checklist-Community FXS Specific Social Avoidance (ABC-C) subscale in patients who have complete methylation of their FMR1 gene. All patients, including the cohort of partially methylated patients, will be included in a key secondary endpoint analysis.

The company performed an analysis of the CONNECT-FX population within those patients having complete methylation of their FMR1 gene (n = 137 of 212 in the intent to treat population) to evaluate the effect of Zygel versus placebo. One patient did not have a post-baseline efficacy measure and was therefore not included in the efficacy analysis.

Baseline demographics for patients with complete methylation of the FMR1 gene are shown below. The group is similar to the previously reported full data set of patients and the cohort of patients with ≥90% methylation. The majority of patients were male and the children had a mean age of 9 to 10 years old.

“The treatment difference versus placebo and p value on the primary endpoint of improvement in the ABC-C Social Avoidance subscale in patients with complete methylation are consistent with the previously reported findings in patients with at least 90% methylation, despite the fact that the study was not powered to evaluate either of these patient populations,” said Dr Joseph Palumbo, chief medical officer at Zynerba.

“We believe the CONNECT-FX trial was instrumental in advancing our understanding of the science of Fragile X Syndrome. We look forward to leveraging what we learned as we seek to confirm our findings in the RECONNECT trial.”

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Immusist Beverage Concentrate - Proprietary blend, formulated to reduce inflammation while hydrating and oxygenating the cells.

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Total 1 comment
    • Saurav

      Here are the top 25 DevOps Interview questions which is asked in DevOps interviews..
      Operating system
      1) What is the distinction among Linux and Unix ?

      2) What’s a KVM ?

      3) How might you ensure a help begins an OS of your decision ?

      4) Here’s a terminal. What kind of Linux is running ?

      5) Write an order to erase all unfilled record under a registry.

      6) What is Active Directory ? How would you make a worker join an area ?

      Systems administration
      1. What is the contrast among TCP and UDP ?

      2. What is ICMP ? For what reason should you block it ?

      3. What is IPv6 ? For what reason should we give it a second thought ?

      4. In a professional workplace clients from London can ping a specific worker however clients from New York can’t, what steps will you take to investigate the issue ?

      5. What steps are expected to change the host name on a Linux machine ?

      6. Where is the host name document on a Windows worker ?

      7. How is a host name settled on a Linux machine ?

      8. What’s a SSL burrow ?

      9. What’s a SDN ?

      Scripting (inquiries here change on rating and rely practically upon advising the individual to compose a short content)
      1. What is your most loved scripting language ? Why ?

      2. What are configuration designs ?

      3. Portray a few contents you have composed/computerization you have done/programs you have composed. Legitimize your decision of scripting language and configuration designs.

      4. Would you be able to port a…

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.